公开(公告)号：US20180193487A1

公开(公告)日：2018-07-12

申请号：US15873488

申请日：2018-01-17

申请人： SEOUL NATIONAL UNIVERSITY HOSPITAL

发明人： Jung-Joon SUNG ,  Seung-Yong SEONG ,  Hee-Woo LEE ,  Ki Yoon Kim

IPC分类号： A61K48/00 ,  A61K35/30 ,  C12N9/24 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/16 ,  A61P25/00 ,  A61P21/00

CPC分类号： A61K48/005 ,  A61K35/30 ,  A61K35/545 ,  A61K38/00 ,  A61P21/00 ,  A61P25/00 ,  C07K14/005 ,  C12N5/0606 ,  C12N5/0619 ,  C12N5/0667 ,  C12N5/0696 ,  C12N5/12 ,  C12N5/16 ,  C12N9/2402 ,  C12N2760/18822 ,  C12N2760/18833

摘要： The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.